CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 113 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,954,098 | -29.1% | 4,991,026 | +3.3% | 0.00% | -25.0% |
| Q2 2023 | $153,631,755 | +40.4% | 4,832,707 | +7.8% | 0.00% | +33.3% |
| Q1 2023 | $109,387,710 | -22.6% | 4,484,941 | +0.1% | 0.00% | -25.0% |
| Q4 2022 | $141,370,577 | +19.4% | 4,482,263 | +7.0% | 0.00% | 0.0% |
| Q3 2022 | $118,363,000 | +8.3% | 4,188,371 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $109,260,000 | -8.0% | 4,132,287 | +21.8% | 0.00% | +33.3% |
| Q1 2022 | $118,735,000 | +5.1% | 3,391,415 | -2.7% | 0.00% | 0.0% |
| Q4 2021 | $112,972,000 | +13.9% | 3,484,657 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $99,217,000 | +46.0% | 3,363,278 | +26.8% | 0.00% | +50.0% |
| Q2 2021 | $67,959,000 | +351.0% | 2,652,558 | +141.7% | 0.00% | – |
| Q1 2021 | $15,070,000 | -17.0% | 1,097,571 | +0.2% | 0.00% | -100.0% |
| Q4 2020 | $18,162,000 | – | 1,095,391 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |